Large cardiovascular and renal outcome trials have demonstrated that sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists confer substantial renoprotective and cardioprotective benefits in patients with CKD and diabetes or cardiovascular disease. Here, GLP1R is linked to diabetes mellitus.